Implantable cardioverter-defibrillator therapy is indicated in all patients with ischaemic cardiomyopathy and severe systolic dysfunction: discussion

14 April 2026 (13:35 - 13:45)

Organised by:

Video

Sign in for access options

5 More presentations in this session

Presentation thumbnail

Implantable cardioverter-defibrillator therapy is indicated in all patients with ischaemic cardiomyopathy and severe systolic dysfunction: pro

Professor C. Sticherling (Basel, CH)

Presentation thumbnail

Implantable cardioverter-defibrillator therapy is indicated in all patients with ischaemic cardiomyopathy and severe systolic dysfunction: con

Professor N. Dagres (Berlin, DE)

Presentation thumbnail

The left bundle branch pacing-shock lead will become standard in implantable cardioverter-defibrillator therapy: pro

Doctor J. Karvonen (Helsinki, FI)

Presentation thumbnail

The left bundle branch pacing-shock lead will become standard in implantable cardioverter-defibrillator therapy: con

Professor G. Upadhyay (Chicago, US)

Presentation thumbnail

The left bundle branch pacing-shock lead will become standard in implantable cardioverter-defibrillator therapy: discussion

Access the full session

Session thumbnail

Debate on cardiac implantable electronic device therapy

The Event

Event poster

EHRA 2026

14 April 2026 13:35 CET

You may be interested in

Congress Session

Debate on primary prevention in ICD therapy

30 March 2025

Congress Session

2022 ESC Guidelines for the management of patients with ventricular arrhythmias and prevention of sudden cardiac death – Meet the Guidelines Task Force

26 August 2022

Congress Presentation

Risk prediction for sudden cardiac death. Insights from PROFID and other projects

1 April 2025

Congress Presentation

Implantable cardioverter-defibrillator

20 May 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources